| Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone E Kastritis, I Dialoupi, M Gavriatopoulou, M Roussou, N Kanellias, ... Blood advances 3 (20), 3002-3009, 2019 | 48 | 2019 |
| Vulvar, perianal and perineal cancer after hidradenitis suppurativa: a systematic review and pooled analysis GM Makris, N Poulakaki, AM Papanota, E Kotsifa, TN Sergentanis, ... Dermatologic Surgery 43 (1), 107-115, 2017 | 46 | 2017 |
| Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy E Terpos, IV Kostopoulos, E Kastritis, I Ntanasis-Stathopoulos, M Migkou, ... HemaSphere 3 (6), e300, 2019 | 27 | 2019 |
| Ki-67 expression as a factor predicting recurrence of ductal carcinoma in situ of the breast: a systematic review and meta-analysis N Poulakaki, GM Makris, AM Papanota, F Marineli, A Marinelis, ... Clinical breast cancer 18 (2), 157-167. e6, 2018 | 27 | 2018 |
| Serum inhibin and leptin: risk factors for pre-eclampsia? G Chrelias, GM Makris, AM Papanota, A Spathis, G Salamalekis, ... Clinica Chimica Acta 463, 84-87, 2016 | 23 | 2016 |
| Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia AM Papanota, I Ntanasis-Stathopoulos, E Kastritis, MA Dimopoulos, ... Journal of Blood Medicine, 291-300, 2019 | 19 | 2019 |
| Real‐world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: a study of the Greco … E Katodritou, E Kastritis, M Gatt, YC Cohen, I Avivi, A Pouli, C Lalayianni, ... American Journal of Hematology 95 (5), 465-471, 2020 | 12 | 2020 |
| Next generation flow cytometry provides a standardized, highly sensitive and informative method for the analysis of circulating plasma cells in newly diagnosed multiple myeloma … E Terpos, IV Kostopoulos, AM Papanota, K Papadimitriou, P Malandrakis, ... Blood 134, 4338, 2019 | 5 | 2019 |
| Carfilzomib-associated renal toxicity is common and unpredictable: An analysis of 114 patients E Kastritis, M Roussou, C Gakiopoulou, E Psimenou, M Gavriatopoulou, ... Blood 132, 1966, 2018 | 4 | 2018 |
| A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors CE Alifieris, K Orfanakos, A Papanota, GP Stathopoulos, N Sitaras, ... Journal of cancer research and clinical oncology 143, 717-725, 2017 | 4 | 2017 |
| The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma PI Artemaki, AM Papanota, P Karousi, C Liacos, CK Kontos, D Patseas, ... Blood 134, 5529, 2019 | 2 | 2019 |
| Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma … E Terpos, M Roussou, I Ntanasis-Stathopoulos, N Kanellias, D Fotiou, ... Blood 132, 1968, 2018 | 2 | 2018 |
| Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First-and Second-Line Therapy with Novel Agents: Results from a Single Center Analysis … E Terpos, N Kanellias, E Kastritis, M Gavriatopoulou, V Koutoulidis, ... Blood 134, 4326, 2019 | 1 | 2019 |
| A molecular signature of three tRNA-derived RNA fragments may discriminate smoldering from symptomatic multiple myeloma patients P Karousi, AM Papanota, PI Artemaki, C Liacos, CK Kontos, D Patseas, ... Blood 134, 5528, 2019 | 1 | 2019 |
| Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS) E Kastritis, I Papassotiriou, M Roussou, M Gavriatopoulou, M Aimilia, ... Blood 134, 3126, 2019 | 1 | 2019 |
| Flow-Mediated Dilatation (FMD) and Aortic Blood Pressure May Predict Cardiovascular Adverse Events During Carfilzomib Therapy: A Prospective Study in Relapsed/Refractory … E Kastritis, A Laina, M Gavriatopoulou, G Georgiopoulos, D Fotiou, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e262, 2019 | 1 | 2019 |
| Primary treatment of light chain (AL) amyloidosis with bortezomib, lenalidomide and dexamethasone (VRD) or with bortezomib, cyclophosphamide and dexamethasone (VCD/CyBorD … E Kastritis, M Gavriatopoulou, D Fotiou, N Kanellias, M Migkou, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e320-e321, 2019 | 1 | 2019 |
| Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events E Kastritis, A Laina, M Gavriatopoulou, G Georgiopoulos, ... Blood 132, 3247, 2018 | 1 | 2018 |
| Ovarian tumors: should the cervix be examined first GM Makris, C Chrelias, A Papanota, MJ Battista, N Papantoniou Eur J Gynaecol Oncol 38 (3), 462-464, 2017 | 1 | 2017 |
| Office Endometrial Cytological Sampling: Examining Predictors of Strenuousness GM Makris, C Siristatidis, N Margari, C Chrelias, AM Papanota, ... in vivo 30 (3), 309-314, 2016 | 1 | 2016 |
